Track Categories
The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.
1.Target Identification & Validation:
This session delves into cutting-edge techniques and strategies to identify and validate promising drug targets, including genomics, proteomics, and bioinformatics approaches. It aims to accelerate drug discovery by pinpointing the most relevant therapeutic targets for various diseases.
1-1 Genomics in target discovery
1-2 Proteomics and drug targets
1-3 Bioinformatics approaches
1-4 Functional Genomics for Target Validation
1-5 Artificial Intelligence and Machine Learning in Target Discovery and Validation
Delve into the unveils the transformative journey of turning promising drug candidates into potential therapies. Explore advanced strategies and techniques in medicinal chemistry and drug, design to refine initial compounds for enhanced potency, safety, and selectivity, propelling them towards clinical development
2-2High-throughput screening
2-3Medicinal chemistry strategies
2-4 Fragment-Based drug Discovery
2-5In silico drug, design and Virtual Screening
Embark on the crucial journey from laboratory to clinic. This session explores the meticulous process of evaluating drug, candidates in animal models, ensuring safety and efficacy before human trials. Delve into pharmacology, toxicology, and pharmacokinetic studies that lay the foundation for successful drug development.
3-1 Animal models for drug testing
3-2 In vitro pharmacology studies
3-3 Preclinical safety assessment
3-4 Pharmacokinetics and Metabolism Studies (PK/DM)
3-5 Formulation Development and Optimization
4 .Clinical Trial design & Management:
Navigate the intricate landscape of clinical trials. This session unveils the art and science of design ing robust studies, ensuring regulatory compliance, recruiting diverse patient populations, and analyzing data to determine the safety and efficacy of new pharmaceutical interventions.
4-2 Endpoint selection and validation
4-3 Patient recruitment and retention
4-4 Clinical Trial Operations and Logistics
4-5Patient-Reported Outcomes (PROs) and Quality of Life Assessments
5 .Regulatory Affairs & Market Approval:
Unlock the pathway to global markets. This session demystifies the intricate regulatory landscape, guiding you through successful submissions and post-marketing strategies to ensure your pharmaceutical innovation reaches patients worldwide.
5-1 Regulatory submission strategies
5-2 Post-market safety monitoring
5-3 Global regulatory landscape
5-4 Intellectual Property (IP) and Regulatory Strategies
5-5 Evolving Regulatory Landscape for Cell and Gene Therapies
6. Synthesis & Process Chemistry:
Unlock the pathway to global markets. This session demystifies the intricate regulatory landscape, guiding you through successful submissions and post-marketing strategies to ensure your pharmaceutical innovation reaches patients worldwide.
6-1 Novel synthesis routes
6-2 Green chemistry in Pharma
6-3 Scaling up Drug production
6-4 Continuous Manufacturing and Process Intensification
6-5 Quality by design (QbD) and Process Analytical Technology (PAT
Elevate the delivery of therapeutic innovation. This session explores the intricate science of crafting optimal Drug formulations, ensuring effective absorption, stability, and bioavailability across diverse delivery routes, ultimately maximizing patient benefit.
7-1 Oral drug delivery optimization
7-2 Injectable formulations
7-3 Stability testing and formulation
7-4 Novel Drug Delivery Systems (NDDS)
7-5 Drug Excipient Compatibility Studies
8.Quality Control & Assurance:
Safeguard the integrity of pharmaceutical excellence. This session delves into the rigorous standards and analytical techniques that ensure product quality, safety, and compliance throughout the manufacturing process, fostering trust in every dose.
8-1Analytical techniques in QC
8-2 GMP compliance and audits
8-3 Quality assurance in pharmaceutical manufacturing
8-4 Sterility Assurance and Aseptic Processing
8-5Risk Management and Quality Systems
9.Continuous Manufacturing & Process Innovation:
Revolutionize pharmaceutical production. This session explores the shift from traditional batch processing to continuous manufacturing, highlighting cutting-edge technologies that streamline production, enhance quality, and enable real-time process monitoring for increased efficiency and agility.
9-1 Implementing continuous manufacturing
9-2 Process analytical technology (PAT)
9-3 Real-time process monitoring
9-4 Machine Learning and Artificial Intelligence in Process Optimization
9-5 Regulatory Considerations for Continuous Manufacturing
Unlocking the potential of complex therapeutics. This session delves into the intricate world of biologics and biosimilars, exploring their development, manufacturing challenges, characterization, and regulatory pathways, ultimately increasing access to life-changing treatments
10-1 Biologics manufacturing challenges
10- 2 Biosimilar characterization
10-3 Biosimilar regulatory pathways
10-4 Immunogenicity and Safety of Biosimilars
10-5 Economic and Market Access Considerations for Biosimilars
11.Pharmacokinetics (PK) & Pharmacodynamics (PD):
Decipher the complex interplay between drug, and body. This session unravels how medications are absorbed, distributed, metabolized, and eliminated (PK), and how they exert their therapeutic or adverse effects (PD), paving the way for optimized dosing and personalized medicine.
11-1 PK/PD modeling and simulation
11-2 Drug metabolism and transport
11-3 Drug Interactions and Adverse Reporting
11-4 Population PK/PD and Individualized Dosing
11-5PK/PD in Special Populations
12. Drug Interactions & Adverse events:
Master the intricate dance of medications within the body. This session unravels the complexities of polypharmacy, exploring how drug, interact, predicting potential adverse events, and equipping healthcare providers with strategies to optimize patient safety and minimize risks.
12-2 Adverse event reporting and management
12-3 Pharmacovigilanc
12-4 Drug- Drug Interaction (DDI) Risk Assessment and Mitigation Strategies
12-5Patient-Specific Factors Influencing Interactions and Adverse Events
This session dives into the nuances of Global development, therapy in pediatric, geriatric, and other special populations, addressing challenges and opportunities for optimizing medication safety and efficacy in these diverse patient groups.
13-1 Pediatric Pharmacology
13-2 Geriatric pharmacology
13-3 Drug therapy in pregnancy
13-4 Therapy in Patients with Renal or Hepatic Impairment
13-5 Pharmacogenomics and Personalized Medicine in Special Populations
Revolutionize healthcare with tailored treatments. This session explores the cutting-edge science of utilizing patients' genetic, environmental, and lifestyle data to create individualized therapies, maximizing effectiveness and minimizing side effects for optimal health outcomes.
14-1 Pharmacogenomics and personalized dosing,
14-2 Biomarker development and validation,
14-3 Companion diagnostics.
14-4 Artificial Intelligence and Machine Learning in Precision Medicine
14-5 Ethical and Regulatory Considerations in Precision Medicine
15. Rare Diseases & Orphan Drugs:
Illuminating the path for underserved patients. This session explores the unique challenges and opportunities in developing treatments for rare diseases, navigating regulatory incentives, and fostering collaboration to bring hope to those affected by these conditions
15-1 Orphan drug design process
15-2 Clinical trial challenges in rare diseases
15-3 Patient advocacy and access
15-4 Therapeutic Innovations for Rare Diseases: Accelerating Development & Improving Patient Outcomes
15-5 Global Perspectives on Rare Disease Research and Drug Development
Transforming drug delivery for optimized therapeutic outcomes. This session explores cutting-edge advancements, from nanoparticles and liposomes to controlled-release and targeted delivery, revolutionizing how medicines reach their destination and enhancing patient experiences
16-1 Nanoparticle drug delivery
16-2 Liposomal formulations
16-3 Targeted drug delivery technologies
16-4 Oral Controlled Release Drug Delivery
16-5 Transdermal Drug Delivery Systems
17.Digital Health & AI in Pharma:
This session explores the transformative potential of artificial intelligence and digital technologies in drug discovery, clinical trials, personalized medicine, and patient care, paving the way for a new era of data-driven healthcare solutions.
17-1 AI in Drug discovery
17-2 Digital biomarkers and patient monitoring
17-3 Real-world data and AI
17-4 Virtual clinical trials and Decentralized Research
18.3D Printing & Personalized Medicine:
Transforming healthcare through customization. This session delves into the innovative use of 3D printing to create patient-specific medications, implants, and medical devices, revolutionizing treatment approaches and enhancing patient care.
18-1 3D printed drug delivery systems
18-2 Personalized dosage forms
18-3 3D bio printing in regenerative medicine
18-4 3D-Printed Prosthetics and Orthotics
18-5 3D-Printed Surgical Models and Guides
19. Regenerative Medicine & Cell Therapies:
Igniting the body's healing potential. This session explores the frontiers of regenerative medicine, delving into cutting-edge cell therapies, tissue engineering, and gene therapies that hold the promise of repairing damaged tissues and organs, offering new hope for patients with chronic and debilitating conditions.
19-1 Stem cell therapies
19-2 Gene therapy approaches
19-3 Ethical considerations in regenerative medicine
19-4 Tissue Engineering and Biomaterials
19-5 Immunotherapy and Immune Modulation in Regenerative Medicine
20 Nanotechnology & Nano medicine:
Harnessing the power of the infinitesimal. This session explores the revolutionary applications of nanoscale materials and devices in medicine, from targeted drug delivery and diagnostics to regenerative therapies and innovative medical imaging, pushing the boundaries of healthcare innovation.
20-1 Nanomaterial’s for diagnostics
20-2 Therapeutic nanoparticles,
20-3 Nano medicine in cancer therapy
20-4 Nanomedicine for Infectious Disease
21. Regulatory Science & Policy
Navigate the evolving landscape of Global development, regulation. This session explores cutting-edge regulatory science, policy trends, and global harmonization efforts to ensure patient safety while fostering innovation and accelerating access to life-changing therapies.
21-1 Evolving regulatory landscape
21-2 Patient-focused drug therapy
21-3 Regulatory harmonization efforts.
21-4 Health Technology Assessment (HTA) and Decision Making
21-5 Value-Based Pricing and Contracting
22. Intellectual Property & Patent Law:
Exploring the intricate world of pharmaceutical innovation protection involves understanding various strategies for securing patents, defending intellectual property rights, and leveraging licensing agreements. This discussion covers the essentials for fostering a thriving environment for groundbreaking global development in Pharma 2024.
22-1Patent strategies for pharmaceuticals
22-2 Licensing and technology transfer
22-3 Bio similar patent litigation.
22-4 Data Exclusivity and Regulatory Data Protection
23.Medical Affairs & Scientific Communication:
Elevate scientific discourse for impactful healthcare solutions. In the Pharma 2024 Conference session, we explore strategies for effective scientific communication, fostering collaboration between medical affairs and healthcare professionals to ensure that evidence-based insights shape clinical practice and improve patient outcomes.
23-1 Medical writing and publication
23-2 Scientific engagement with healthcare professionals
23-3 Medical information management.
23-4 Evidence Generation and Real-World Data
23-5 Patient-Focused Communication and Advocacy
24. Ethical Considerations in Pharma:
Defining a responsible course in pharmaceutical innovation. In the Pharma 2024 Conference session, we explore the ethical complexities surrounding drug development, marketing, pricing, and access, seeking to foster a transparent and equitable healthcare landscape that prioritizes patient well-being and societal benefit.
24-1 Research ethics in clinical trials
24-2 Pricing and access to medicines
24-3 Ethical Marketing and Promotion of pharmaceuticals
24-4 Ethical Considerations in Global Health and Access to Medicines
25. Real-World Evidence (RWE) & Post-Market Surveillance:
In the Pharma 2024 Conference session, we explore the growing importance of real-world evidence (data collected outside of traditional clinical trials) in evaluating drug safety and effectiveness in real-world settings. It also covers the role of post-market surveillance in identifying and mitigating risks associated with marketed drugs.
25-1 RWE study design and methodology
25-2 Integrating RWE with clinical trial data
25-3 Post-market safety monitoring and pharmacovigilanc
25-4 RWE in regulatory decision-making
26. Drug Repurposing & Drug Combinations:
That session in the Pharma 2024 focuses on innovative approaches to drug combinations, including repurposing existing drugs for new indications and exploring the potential of these combinations to improve therapeutic outcomes.
26-1 Rational drug design combination
26-2 clinical trials for drug designs
26-3 Regulatory considerations for drug, repurposing and combinations
26-4 Repurposing Drug Identifying New Uses for Old Medications
26-5 Combination Therapies: Optimizing Drug Efficacy and Safety through Synergy
27. Pharmaceutical Microbiology & Sterility Assurance:
Pharma 2024 will feature a presentation examining the pivotal role of microbiological principles in Pharma manufacturing and quality control, underscoring the necessity of sterility assurance to prevent contamination and safeguard patient safety..
27-1 Microbiological contamination control strategies
27-2 Sterilization methods and validation
27-3 Environmental monitoring programs
27-4 Microbial risk assessment and mitigation
28. Pharmaceutical Packaging & Labeling:
This session addresses the latest developments in pharmaceutical packaging and labeling technologies, focusing on their role in protecting drug products, ensuring product integrity, and providing essential information to patients and healthcare professionals.
28-1 Pharma Innovative packaging materials and designs
28-2 Smart packaging and anti-counterfeiting measures
28-3 Labeling regulations and compliance
28-4 Patient-centric packaging design
29. Global Health & Access to Medicines:
The Pharma 2024 Conference will include a forum that examines the challenges and opportunities in ensuring equitable access to medicines in low- and middle-income countries, addressing issues such as affordability, intellectual property rights, and regulatory barriers.
29-1 Global health disparities and the need for access to medicines
29-2 Pricing and reimbursement strategies
29-3 Intellectual property rights and access to medicines
29-4 Local Manufacturing and Technology Transfer
29-5 Public-Private Partnerships (PPPs) for Global Health
Case studies and reports in the pharmaceutical industry act as a compass, guiding stakeholders through the complex landscape of drug development and healthcare delivery. They provide a firsthand account of impacts and setbacks, offering actionable insights and lessons learned that can shape future strategies, policies, and ultimately, improve patient outcomes.
30-1 Drug Discovery & Development
30-2 pharmaceutical Chemistry & Manufacturing
30-3 Clinical Pharmacology & Therapeutics
30-4 Regulatory Affairs & Market Access
30-5 Real-World Evidence & Post-Market Surveillance